Nymox Pharmaceutical Corp. (NASDAQ: NYMX} has confirmed they are re-domiciling in the Bahamas.
This follows shareholder approval and Corporations Canada agreeing to the change.
HASBROUCK HEIGHTS, N.J. — Nymox Pharmaceutical Corp. (NASDAQ: NYMX} is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas, effective July 31, 2015.
At the Special Shareholders Meeting of Nymox on April 23, 2015 there was a 94% majority shareholder vote in favor of the Company’s change of domicile to the Bahamas.
Subsequent to the majority vote in favor, on July 31, 2015 the Company was informed that it has received formal approval from Corporations Canada. The Company’s Management are located in Bahamas, the U.S. and Europe. The Company currently maintains offices in the Bahamas, the U.S. and Canada.
The Company recently announced that it’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies.
The Company now intends to meet with authorities and to proceed to file where possible, in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories.
Nymox has also recently reported a successful Phase 2 long-term outcome study in 147 men of NX-1207 at higher dosage for low grade localized prostate cancer.
The July 27th webcast of news and discussion by experts of the Company’s new clinical trial results can be viewed at
The link is also available at the Company’s website.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH, the potential of NX-1207 to treat BPH and the estimated timing of further developments for NX-1207. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on NX-1207, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of NX-1207. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.
Paul Averback Nymox Pharmaceutical Corporation